Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML2012: DaunoXome and FLADx in Pediatric AML
NCT01828489Phase 3Unknown
- Sponsor
- Region Västra Götaland
- Start
- Mar 2013
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 9
01
Overview
A Phase 3 trial of daunorubicin, fludarabine in acute myeloid leukemia (AML), sponsored by Region Västra Götaland. Status: unknown.
02
Drugs
daunorubicinfludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01828489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01828489.